Yamagata, M., Tsuchishima, M., Saito, T., Tsutsumi, M
By affecting both metabolic and neurodegenerative pathways, GLP-1RAs represent a multi-target approach to the treatment of PD, offering hope for improving patient outcomes
The appetite suppression, enhanced satiety, and metabolic effects persist as long as the medication remains active
1 Dual agonism of GIP and GLP-1 receptors is a promising new approach currently in clinical development for the treatment of diabetes, obesity, and associated complications [1] The incretin effect defines the main physiological role of GIP and GLP-1 GIP and GLP-1 increase insulin secretion following nutrient-induced secretion from the gut (incretin effect): There is a stronger insulin secretion response to oral compared to 'isoglycemic' intravenous glucose administration due to secretion and action of incretin hormones